Cambridge, United Kingdom

Christopher Stephen Frampton

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christopher Stephen Frampton: Innovator in Pharmaceutical Applications

Introduction

Christopher Stephen Frampton is an inventor based in Suffolk, GB. He is known for his innovative work in the field of pharmaceuticals. Although he currently holds no granted patents, his contributions to the development of new pharmaceutical compositions are noteworthy.

Latest Patent Applications

Frampton's latest patent applications include the invention of tetrahydrocannabinolic acid cocrystals. This invention discloses various cocrystals, such as a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D,L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid ethyl maltol cocrystal, and a 1:1 tetrahydrocannabinolic acid caffeine cocrystal. The invention also relates to pharmaceutical compositions containing these cocrystals and methods for treating diseases, disorders, or conditions by administering a therapeutically effective amount of the cocrystal or a pharmaceutical composition containing it. Additionally, he has developed novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. This invention also includes compositions and methods for using these salts in the treatment of gastrointestinal and/or genitourinary disorders.

Conclusion

Christopher Stephen Frampton is an innovative inventor whose work in pharmaceutical applications shows great promise for future developments in the field. His latest patent applications reflect a commitment to advancing medical treatments through novel compositions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…